Delivery Order SPE2DB25D2207-SPE2DB25FQRTF
- Not listed
- The Defense Logistics Agency awarded a $5,574.45 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3mL) on September 2, 2025, with an ultimate completion date of September 3, 2025. This is a firm fixed-price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $3,759.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on August 25, 2025, with an ultimate completion date of August 26, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $17,574.08 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on September 9, 2025, with completion targeted for September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $8,411.34 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL). The contract utilizes firm fixed price terms and is classified as a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 4, 2025. The point of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and primary...
- The Defense Logistics Agency awarded a $33,160.61 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL), with completion targeted for August 20, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where the vendor maintains its corporate office and...
- The Defense Logistics Agency awarded a $8,247.08 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml), a diabetes medication. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of September 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $11,848.26 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) on September 4, 2025, with a completion date of September 5, 2025. This is a firm fixed-price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is listed as...
- The Defense Logistics Agency awarded a $37,417.19 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens in 3 mL formulations, with completion targeted for September 15, 2025. This competitively awarded, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader relationship...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) under a firm fixed-price contract valued at $11,505.44. The award was made on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999...
- The Defense Logistics Agency awarded a $27,396.14 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded contract utilizes firm fixed pricing with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB25D2207Indefinite Delivery Contract
- SPE2DB25D2207-SPE2DB25FQRTFDelivery Order
The Defense Logistics Agency awarded a $13,578.99 delivery order to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3 mL) with a completion date of September 15, 2025. This is a firm fixed-price, non-set-aside contract awarded on September 12, 2025, with fulfillment based at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as the primary vehicle for pharmaceutical supply to military and federal healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was selected through competitive procurement to supply this diabetes medication in support of federal medical supply needs. The company maintains an extensive portfolio of federal pharmaceutical contracts with DLA covering a diverse range of therapeutic products including specialty medications, vaccines, and medical devices. This particular delivery order represents one of numerous competitively awarded transactions under the company's prime IDC with DLA, reflecting its established capability to meet federal procurement requirements for critical pharmaceutical commodities supporting military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.6k | 9/12/25 |